🩸 New #JACCBTS study reveals estrogen’s dual effects on microvascular health differ by sex ⚖️ A balanced ceramide: S1P ratio is 🔑 to endothelial health 🧬 May explain why long-term hormone exposure can 📈 CV risk https://t.co/YzwVoh8QNu #APSSexDiff2025 @gogo_gopss @LabFreed

The DOSE Trial: In a multicenter RCT (n=1,001), operator radiation exposure was compared between left distal radial vs right transradial access at left wrist, head, and chest. No significant differences. https://t.co/Pun5k2YZqz #TCT2025 #JACCINT

FTMO Verified prop traders walk their path. Rise now and start your FTMO Challenge!

FFR-guided #PCI using zotarolimus DES provides significantly better long-term value than CABG for treatment of patients with multivessel CAD, with equivalent clinical outcomes at substantially lower cost. https://t.co/eXK1yE4OLF #TCT2025 #JACC #cvCABG #cvCAD @wfearonmd

Big ideas. Breakthrough science. Real-world impact 💡 The #JACCJournals family brings interventional innovation to #TCT2025, from late-breaking trials to transformative device advances 👉 https://t.co/xqMg3NTmRg #JACC #JACCINT #JACCCaseReports #JACCAdvances @TCTConference

A new era in #pericarditis care is unfolding. 🌟 Next-gen therapies & advanced imaging, especially cardiac #MRI, are reshaping diagnosis, reducing relapses, & improving outcomes worldwide. Explore the future in this #JACCAdvances review: https://t.co/Qoe4drC9yj @AllanLKleinMD1

How to DECIDE amongst strategies in patients with plaque by #YesCCT? The rationale and design of the AI-DECIDE study aims to evaluate changes in medical therapy and revascularization decisions based on the findings from #AI-ML cardiac CT analysis. https://t.co/04bAcpHJMx #JACCIMG

Even small changes in #alcohol intake can impact #BP. 🍷➡️📉 Reducing or stopping drinking may lead to meaningful BP improvements and better management. https://t.co/3Sjen55xkA #JACC #Hypertension #BloodPressure

💔🎗️ #Anthracyclines save young lives but can harm the heart 📊 New intl guidelines outline 🔑 dose risks: ➡️ Daunorubicin ≈ 0.6× doxorubicin ⬆️ Mitoxantrone ≈ 10.5× higher Personalized dosing = stronger hearts after cancer therapy https://t.co/Vm5nABgDt0 #JACCCardioOnc #cvPed

Mitral isthmus block facilitated by EIVOM is feasible and safe, with procedure and fluoroscopy times that are not significantly different from those of control patients. https://t.co/i3Gq4rU7MW

Research led by @DrDanDonner at @BakerResearchAu has shown that a new drug could reprogram the immune system after severe heart attacks to dampen heart damage & promote heart repair. Get the details in #JACCBTS: https://t.co/tfxr6mwNLO

Genetic CMPs are an under-recognized cause of #HF. Pathogenic variants: ~20% in #DCM, ~30% in HCM, & up to 45% in advanced HF, yet <2% of eligible patients undergo testing. A call to advance precision medicine in HF care? https://t.co/HmhfClOdnT #JACCHF #cvHCM #HeartFailure

New #JACCCaseReports series details 3 cases of acute hemodynamic instability after #TTVR: 1️⃣ RV–PA uncoupling 2️⃣ Myocardial ischemia–triggered AHI 3️⃣ Vasoplegia from inflammatory response 🔗 https://t.co/42nP3w0AAf

μFR functional significance of coronary artery stenosis of target vessels is associated with 1-year graft patency after off-pump CABG, with an optimal cutoff value of 0.77. Read here: https://t.co/Dp3XkZzGqv #JACCINT #CardioX #cvCABG @jkang1026

Compared with targeting <140 mm Hg, targeting <120 mm Hg halved the risk of hemorrhagic #stroke and did not increase that of ischemic stroke. The stroke-preventing effect emerged after 1 year of intervention. Future studies are needed https://t.co/qB7ZmR2klb #JACC

Dr. @junyasuhara, et al describe Notch1;Gata5 compound mutant mice as a novel mouse model of highly penetrant congenital aortic valve disease displaying bicuspid aortic valve and progressive aortic valve stenosis https://t.co/tacf3AkYyK #JACCBTS #cvPed #CHD

Catheter ablation for persistent #AFib resulted in a significant incremental improvement in #QoL over long-term follow-up. The sustained nature of QoL improvement over 3 years following ablation argues against a placebo effect https://t.co/Dprk3fOMLL #JACCCEP #epAblation #EPeeps

Big news for #JACCJournals! #JACCAsia and #JACCAdvances are approved for #ImpactFactor, with first rankings being issued in June. Launched in 2021 and 2022, respectively, both journals are shaping the future of #Cardiology. https://t.co/qswZPE4Jng #CardioX @CandiceSilvers1

DEADLINE EXTENDED: Oct. 22 #JACCAdvances seeks a visionary leader in CV research as its next Editor-in-Chief. Applicants should have an academic post, a strong scholarly record, leadership experience, and knowledge of open access publishing. Apply: https://t.co/u69ewQHR6G

#JACCCardioOnc continues to rise, with a new Impact Factor of 13.4 and a top 10 ranking. The journal’s growing influence highlights its role as a leading platform for cutting-edge #CardioOnc research. https://t.co/2SWhubOMFI @DrBonnieKy

Over 2 decades, maternal #HF rose 66% in Sweden. Among >2M deliveries: 0.34 cases/1,000; ~half had cardiac disease. Comorbidities explain only part of the rise, highlighting the need for ⬆️awareness & management. https://t.co/Y0CEALsjQy #JACCHF #CardioObstetrics #CardioOB